Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

OBJECTIVE--To assess the safety and efficacy of a preparation of mesalazine (5-aminosalicylic acid) coated with a pH dependent resin (Eudragit L) as compared with sulphasalazine in patients with active mild to moderate ulcerative colitis. DESIGN--Eight week randomised double blind parallel group study. SETTING--Forty six gastroenterology outpatient clinics in seven countries. PATIENTS--Two hundred and twenty patients aged 18-70 who met the following criteria: clinical activity index greater than or equal to 6 and endoscopic index greater than or equal to 4; no concomitant treatment for ulcerative colitis; no hypersensitivity to salicylates or sulphonamides. Of the 164 patients eligible for efficacy analysis, 87 received the coated preparation of mesalazine and 77 sulphasalazine. Most of the remaining patients (28 in each group) were ineligible for the efficacy analysis because of treatment with steroid enemas. All pretrial characteristics were comparable in the two treatment groups. INTERVENTIONS--Coated mesalazine (Mesasal) 1.5 g daily or sulphasalazine 3.0 g daily for eight weeks. Compliance monitored by pill counts. END POINT--Clinical and endoscopic remission. MEASUREMENTS AND MAIN RESULTS--Clinical activity measured by daily diary cards, assessment by investigators, and laboratory findings. Endoscopic evaluation at week 8. After four weeks 50 of 70 patients (71%) taking coated mesalazine and 38 of 58 (66%) taking sulphasalazine had achieved remission of their disease by eight weeks remission rates were 74% (37/50 patients) and 81% (35/43) in the two treatment groups respectively. Endoscopic remission at eight weeks was recorded in 20 of 41 patients (49%) taking coated mesalazine and 18 of 38 (47%) taking sulphasalazine. There was a higher incidence of adverse events among patients taking sulphasalazine (25/105; 24%) than among those taking coated mesalazine (16/115; 14%). CONCLUSION--Mesalazine coated with Eudragit L is a safe, logical alternative to sulphasalazine.

[1]  S. Riley,et al.  Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. , 1988, Gut.

[2]  Greenberg Gr,et al.  Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. , 1988 .

[3]  G. Greenberg,et al.  Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. , 1988, The American journal of gastroenterology.

[4]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[5]  J. Hardy,et al.  Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease , 1987, Alimentary pharmacology & therapeutics.

[6]  W. Kraaz,et al.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. , 1986, Gastroenterology.

[7]  I. Donald,et al.  The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. , 1985, Postgraduate medical journal.

[8]  C. H. Mason,et al.  Olsalazine in active ulcerative colitis. , 1985, British medical journal.

[9]  C. O'Morain,et al.  Reversible male infertility due to sulphasalazine: studies in man and rat. , 1984, Gut.

[10]  J. Shaffer,et al.  SULPHASALAZINE-INDUCED INFERTILITY REVERSED ON TRANSFER TO 5-AMINOSALICYLIC ACID , 1984, The Lancet.

[11]  W. Stenson,et al.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. , 1984, Gastroenterology.

[12]  A. Harries,et al.  TREATMENT OF ULCERATIVE COLITIS WITH ORAL 5-AMINOSALICYLIC ACID IN PATIENTS UNABLE TO TAKE SULPHASALAZINE , 1983, The Lancet.

[13]  K. Das,et al.  Sulfasalazine. Adverse effects and desensitization. , 1983, Digestive diseases and sciences.

[14]  J. Rhodes,et al.  An oral preparation to release drugs in the human colon. , 1982, British journal of clinical pharmacology.

[15]  U. Zor,et al.  Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. , 1981, Gastroenterology.

[16]  G. Labó,et al.  TREATMENT OF ULCERATIVE COLITIS WITH HIGH-DOSE 5-AMINOSALICYLIC ACID ENEMAS , 1981, The Lancet.

[17]  B. Miller.  [Side effects of salicylazosulfapyridine therapy]. , 2008, Deutsche medizinische Wochenschrift.

[18]  K Heinkel,et al.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. , 1980, The New England journal of medicine.

[19]  J. V. van Tongeren,et al.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. , 1980, Gut.

[20]  C. E. Kelly,et al.  Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature. , 1979, The American journal of gastroenterology.

[21]  H. Mekhjian,et al.  National Cooperative Crohn's Disease Study: adverse reactions to study drugs. , 1979, Gastroenterology.

[22]  A. Traub,et al.  MALE INFERTILITY DUE TO SULPHASALAZINE , 1979, The Lancet.

[23]  A. Levi,et al.  MALE INFERTILITY DUE TO SULPHASALAZINE , 1979, The Lancet.

[24]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[25]  J. Lennard-jones,et al.  Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. , 1977, Gut.

[26]  L. Binderup,et al.  Actinomycin D Peritonitis in Rats , 1976 .

[27]  R. Pounder,et al.  Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. , 1975, Gut.

[28]  S. Truelove,et al.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) , 1973, Gut.

[29]  J. McManus,et al.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. , 1973, The New England journal of medicine.

[30]  W. Swaim,et al.  Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis. , 1972, Minnesota medicine.

[31]  J. Sokal,et al.  Sulfapyridine-induced serum-sickness-like syndrome associated with plasmacytosis, lymphocytosis and multiclonal gamma-globulinopathy. , 1969, The New England journal of medicine.

[32]  J. Collins.  Adverse Reactions to Salicylazosulfapyridine (Azulfidine) in the Treatment of Ulcerative Colitis , 1968, Southern medical journal.

[33]  J. H. Baron,et al.  CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS , 1965 .